Japan Cancer Center Looks To Leverage Expertise As It Builds Pharma Ties
Tissue Samples A Key Resource
Executive SummaryJapan's largest cancer center is looking to build on its tissue sample and genomic resources to further build its reputation as a partner facility for the pharma industry's oncology trials.
You may also be interested in...
The main priorities for the new chief executive of Japan’s drugs regulator over the next five years include putting patients first by promoting early access while ensuring safety, further strengthening pharmacovigilance as new forms of therapy come through, and increasing collaboration with Asia, as the agency looks to meet the challenges of changing technologies.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?